Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting - A new standard of care in relapsed or refractory Hodgkin lymphoma?

Annals of Hematology

Volumn 88, Issue 11, 2009, Pages 1107-1112

  Todd, Anthony ^a   Raj, S ^a   Camilleri, D ^a   Stafford, G ^a   Bulusu, R ^a   Follows, G ^a   Williams, M ^a   Marcus, R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Hodgkin's lymphoma; Salvage chemotherapy; Transplant

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; DOMPERIDONE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHYLPREDNISOLONE; NAVELBINE; ONDANSETRON; PREDNISOLONE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ESAP PROTOCOL; HEMOPOIETIC GROWTH FACTOR;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; CYTOPENIA; DRUG COST; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING; AUTOTRANSPLANTATION; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; DRUG SCREENING; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CISPLATIN; COMBINED MODALITY THERAPY; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 70349434837     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0734-6     Document Type: Article

References (21)

1. Duggan DB, Petroni GR, Johnson JL et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614. doi: 10.1200/JCO.2003.12.086
2. DeVita VT Jr, Hubbard SM (1993) Hodgkin's disease. N Engl J Med 328:560-565. doi: 10.1056/NEJM199302253280808
3. Aparicio J, Segura A, Garcera S et al (1999) ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10:593-595. doi: 10.1023/ A:1026454831340
4. Akhtar S, El Weshi A, Abdelsalam M et al (2007) Primary refractory Hodgkin's lymphoma: Outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant 40:651-658. doi: 10.1038/sj.bmt.1705792
5. Brice P (2008) Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol ***:3-13. doi: 10.1111/ j.1365-2141.2008.06998.x
6. Santoro A, Bredenfeld L, Devizzi L et al (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicentre phase II study. J Clin Oncol 18:2615-2619
7. Santoro A, Magagnoli M, Spina A et al (2007) Ifosfamide, gemcitabine and Vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92:35-41. doi: 10.3324/haematol.10661
8. Baetz T, Belch A, Couban S et al (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14:1762-1767. doi: 10.1093/annonc/mdg496
9. Chau I, Harries M, Cunningham D et al (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haem 120:970-977. doi: 10.1046/j.1365-2141.2003.04226.x
10. Waters J, Chau I, Norman AR et al (2004) Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 22(14S):6589 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
11. Ng M, Waters J, Cunningham D et al (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352-1357
12. Popat U, Hosing C, Saliba RM et al (2004) Prognostic factors for disease progression after HDT and ASCT for recurrent or refractory Hodgkin lymphoma. Bone Marrow Transplant 33:1015-1023. doi: 10.1038/ sj.bmt.1704483
13. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586. doi: 10.1200/ JCO.2006.09.2403
14. Pfreundschuh MG, Rueffer U, Lathan B et al (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12:580-586
15. Martin A, Fernandez-Jimenez MC, Caballero MD et al (2001) Long-term follow up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 113:161-171. doi: 10.1046/j.1365-2141.2001.02714.x
16. Rodriguez J, Rodriguez MA, Fayad L et al (1999) ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93:3632-3636
17. Ribrag V, Nasr F, Bouhris JH et al (1998) VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 21:969-974. doi: 10.1038/sj.bmt.1701202
18. Moskowitz CH, Nimer SD, Zelenetz AD et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 97:616-623. doi: 10.1182/blood.V97.3.616
19. Josting A, Rudolph C, Reiser M et al (2002) Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13:1628-1635. doi: 10.1093/annonc/mdf221
20. Canales MA, Fernandez-Jimenez MC, Martin A et al (2001) Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 86:494-498
21. Joint Formulary Committee British National Formulary (2008) Beccles. Pharmaceutical Press, London